Global Specialty Generics Market

Global Specialty Generics Market Size, Share, Growth Analysis, By Type(Oral, injectable), By Application (Oncology, neurology) - Industry Forecast 2023-2030

Report ID: SQMIG55E2022 | Region: Global | Published Date: August, 2023 | Pages: 157 | Tables: 65 | Figures: 75

To request a free sample copy of this report, please complete the form below.
What people say about us!

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

logos logos logos logos logos
Analyst Support
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.



Global Specialty Generics Market size was valued at USD 67.2 billion in 2021 and is poised to grow from USD 80.13 billion in 2023 to USD 148.38 billion by 2030, at a CAGR of 9.2% during the forecast period (2023-2030).

The global specialty generics market features intense competition among pharmaceutical companies, including industry giants and emerging players. Established firms like Teva, Mylan, and Sandoz dominate with their wide product portfolios, extensive distribution networks, and strong R&D capabilities. New entrants, often focusing on niche therapeutic areas, strive to capture market share through innovation and strategic partnerships. Regulatory complexities and patent challenges create barriers to entry, favoring companies with legal expertise. As market demand shifts towards personalized medicine and complex formulations, companies capable of swift adaptation and offering high-quality, cost-effective specialized generics are poised to thrive in this competitive landscape. 'Teva Pharmaceutical Industries Ltd - Israel', 'Mylan N.V. - USA', 'Sandoz International GmbH (a division of Novartis) - Switzerland', 'Sun Pharmaceutical Industries Ltd - India', 'Lupin Limited - India', 'Dr. Reddy's Laboratories Ltd - India', 'Apotex Inc. - Canada', 'Endo International plc - Ireland', 'Aspen Pharmacare Holdings Limited - South Africa', 'Mayne Pharma Group Limited - Australia', 'Perrigo Company plc - Ireland', 'Glenmark Pharmaceuticals Ltd - India', 'Amneal Pharmaceuticals LLC - USA', 'Hikma Pharmaceuticals PLC - Jordan', 'Fresenius Kabi AG - Germany', 'Aurobindo Pharma Limited - India', 'Zydus Cadila - India', 'Cipla Limited - India', 'Torrent Pharmaceuticals Ltd - India', 'Alvogen - USA'

Specialty generics are often more affordable alternatives to brand-name specialty drugs, making them an attractive option for patients and healthcare providers seeking cost-effective treatment options. As healthcare costs continue to rise, the demand for affordable medications, especially for complex and chronic conditions, drives the growth of the specialty generics market.

Specialty generics are characterized by their complexity, often involving intricate formulations, delivery mechanisms, or manufacturing processes. One key trend was the growing demand for complex generics, which are more challenging to develop and manufacture than traditional generic drugs. These complex generics often require a higher level of expertise and investment, but they can offer significant cost savings compared to the brand-name counterparts. Examples include extended-release formulations, inhalation devices, transdermal patches, and biosimilars. The market was seeing an expansion of specialty generics that addressed various therapeutic areas such as oncology, central nervous system disorders, and autoimmune diseases.

North America, particularly the United States, has historically been a major market for specialty generics due to its well-established healthcare infrastructure and large patient population. The presence of a strong regulatory framework and a favorable reimbursement environment has contributed to the growth of this market in the region.

Feedback From Our Clients

Global Specialty Generics Market

Product ID: SQMIG55E2022